Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.7.2979

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients  

Shi, Liang (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Wu, Li-Li (Wenzhou Medical University)
Yang, Jian-Rong (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Chen, Xiao-Fei (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Zhang, Yi (Department of liver and gall Surgery, The First Affiliated Hospital of Wenzhou Medical University)
Chen, Zeng-Qiang (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Liu, Cun-Li (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Chi, Sheng-Ying (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Zheng, Jia-Ying (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Huang, Hai-Xia (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Yu, Fu-Jun (Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University)
Lin, Xiang-Yang (Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.7, 2014 , pp. 2979-2986 More about this Journal
Abstract
Background: Recently, peroxiredoxin3 (PRDX3) was identified as a novel molecular marker for the progression of hepatocellular carcinoma (HCC). However, its potential clinical application as a serum marker for the early diagnosis and prognosis of HCC has not been investigated. Methods: PRDX3, alpha-fetaprotein (AFP), and other biochemical parameters were measured in serum samples from 297 Chinese patients, including 96 with HCC, 98 with liver cirrhosis (LC), and 103 healthy controls (HCs). Correlations between serum PRDX3 expression and clinicopathological variables and the relationship between serum PRDX3 expression and prognosis were analyzed. Results: Serum PRDX3 was significantly higher in HCC patients than in the LC and HC groups. The sensitivity and specificity of serum PRDX3 for the diagnosis of HCC were 85.9% and 75.3%, respectively, at a cutoff of 153.26 ng/mL, and the area under the curve was 0.865. Moreover, serum PRDX3 expression was strongly associated with AFP level, tumor diameter, TNM stage, and portal vein invasion. Kaplan-Meier curve analysis revealed that HCC patients with high serum PRDX3 expression had a shorter median survival time than those with low PRDX3 expression. Moreover, serum PRDX3 expression was an independent risk factor for overall survival. The inverse correlation between serum PRDX3 and patient survival remained significant in patients with early-stage HCC and in those with normal serum AFP levels. Conclusions: Serum PRDX3 can be used as a noninvasive biomarker for the diagnosis and/or prognosis of HCC.
Keywords
Alpha-fetoprotein; peroxiredoxin3; hepatocellular carcinoma; biomarker;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Song IS, Kim HK, Jeong SH, et al (2011). Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci, 12, 7163-85   DOI
2 Rabilloud T, Heller M, Gasnier F, et al (2002). Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem, 277, 19396-401.   DOI   ScienceOn
3 Shariff MI, Cox IJ, Gomaa AI, et al (2009). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol, 3, 353-67.   DOI   ScienceOn
4 Shen Q, Fan J, Yang XR, et al (2012). Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol, 13, 817-26.   DOI
5 Trachootham D, Alexandre J, Huang P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 8, 579-91.   DOI   ScienceOn
6 Wonsey DR, Zeller KI, Dang CV (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA, 99, 6649-54.   DOI
7 Wu XY, Fu ZX, Wang XH (2010). Peroxiredoxins in colorectal neoplasms. Histol Histopathol, 25, 1297-303.
8 Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82.   DOI
9 Liu L, Zhang CZ, Cai M, et al (2012). Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One, 7, 41293.   DOI
10 Kim K, Yu M, Han S, et al (2009). Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep, 21, 1391-96.
11 Kudo M. (2010) Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology, 78, 1-6.
12 Li XQ, Zhang SL, Cai Z, et al (2009). Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett, 275, 109-16.   DOI
13 Liu X, Feng R, Du L (2010). The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett, 584, 3185-92.   DOI
14 Mao Y, Yang H, Xu H, et al (2010). Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, 59, 1687-93.   DOI   ScienceOn
15 Marquardt JU, Galle PR, Teufel A (2012). [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy]. Dtsch Med Wochenschr, 137, 855-60.   DOI
16 Qiao B, Wang J, Xie J, et al (2012). Detection and identification of by a proteomic approach. Int J Mol Med, 29, 832-40.
17 Marra M, Sordelli IM, Lombardi A, et al (2011). Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med, 9, 171.   DOI
18 Nagasue N (1998). Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg, 5, 7-13.   DOI   ScienceOn
19 Pateron D, Ganne N, Trinchet JC, et al (1994). Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol, 20, 65-71.   DOI   ScienceOn
20 Dietz KJ, Horling F, Konig J, Baier M (2002). The function of oroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot, 53, 1321-29.   DOI   ScienceOn
21 Basu A, Banerjee H, Rojas H, et al (2011). Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate, 71, 755-65.   DOI
22 Breuhahn K, Gores G, Schirmacher P (2011). Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology, 53, 2112-21.   DOI
23 Dai Z, Yin J, He H, et al (2010). Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics, 10, 3789-99.   DOI
24 Fu J, Qiu H, Cai M, et al (2013). Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci, 104, 508-15.   DOI
25 Ji D, Lu ZT, Li YQ, et al (2014) MACC1 expression correlates with pfkfb2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 999-100   과학기술학회마을   DOI
26 Huang HC, Zheng S, VanBuren V, Zhao Z (2009). Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat, 9, 219-30.
27 Huh JY, Kim Y, Jeong J, et al (2012). Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal, 16, 229-43.   DOI
28 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
29 Jo M, Nishikawa T, Nakajima T, et al (2011). Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroentero, 46, 809-21.   DOI   ScienceOn
30 Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91.   DOI   ScienceOn